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Background: B-type natriuretic peptide (BNP) is a strong predictor of mortality in adult patients with various forms
of pulmonary hypertension (PH) and may be a strong prognostic marker in extremely low birth weight (ELBW)
infants with bronchopulmonary dysplasia (BPD) associated PH as well. We sought to assess the relationship
between BNP levels and all-cause mortality in a cohort of ELBW infants with BPD and PH.
Methods: We retrospectively identified ELBW infants with BPD and PH who had serum BNP levels measured as part
of routine clinical care in the neonatal intensive care unit. Peak serum BNP levels were correlated with survival to
discharge or death.
Results: Thirty-six ELBW infants (mean gestational age 26.0 ± 1.9 weeks and mean birth weight 740 ± 290 grams)
with BPD and PH had available survival data and had serum BNP levels measured. Peak BNP level was significantly
lower among infants who survived than among those who died (128 pg/ml, [IQR 23 to 463] vs. 997 pg/ml, [IQR 278
to 1770], P < 0.004). On multivariate Cox proportional hazard analysis, BNP predicted survival independent of age,
gender, and BPD severity. Area under receiver operator characteristic analysis identified a BNP value of 220 pg/ml to
have 90% sensitivity and 65% specificity in predicting mortality.
Conclusion: BNP estimation may be useful as a prognostic marker of all-cause mortality in ELBW infants with BPD
associated PH.
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Pulmonary hypertension (PH) is increasingly recognized as
an important complication of prematurity and bronchopul-
monary dysplasia (BPD) [1,2]. Retrospective studies have
estimated that 25 to 37% of infants with BPD develop PH
[3,4], and a recent prospective study showed that 1 out of 6
extremely low birth weight (ELBW) infants develop PH [5].
This is concerning as PH in the BPD population is associ-
ated with worse outcomes, with mortality rates ranging
between 14% and 38% in retrospective studies [3,4,6-8]
and 12% in one prospective study [5]. Currently there
are no clear guidelines for assessment and monitoring* Correspondence: bsims@peds.uab.edu
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unless otherwise stated.of ELBW infants with PH [9]. Identification of a widely
available biomarker with strong prognostic information is
highly desirable for risk stratification and management.
B-type natriuretic peptide (BNP), a cardiac biomarker
released by myocytes in response to ventricular stretch
[10], is an established marker of ventricular dysfunction
[11]. In adult patients with PH, levels of BNP correlate
with hemodynamic parameters of disease severity and
has been shown to be predictive of survival [12-16]. It is
possible that BNP could also prove useful in assessing
severity and prognosis of ELBW infants with BPD and PH.
The purpose of this present study is to evaluate the utility
of BNP as a potential marker for predicting mortality
among ELBW infants with BPD and PH.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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This retrospective cohort study was conducted in the
Neonatal Intensive Care Units at the University of
Alabama at Birmingham Hospital and Children’s of
Alabama Hospital between August 2010 and December
2012. This study was approved by the University of
Alabama at Birmingham Institutional Review Board,
with waiver of informed consent.
Study population
We identified from the neonatology database all ELBW
infants with BPD in whom serum BNP concentrations
were measured as part of routine clinical assessment for
PH. Diagnosis of BPD was based on the National Institute
of Health consensus definition [17]. Diagnosis of PH was
based on the presence of at least 1 of the following echo-
cardiographic findings: (1) presence of elevated tricuspid
regurgitation jet, (2) flattening of intraventricular septum,
(3) right ventricular hypertrophy, or (4) right to left
shunting. Echocardiogram studies were performed by
certified technicians using Sonos 5500 ultrasound machine
(Philips Healthcare) and were independently interpreted
and reported by pediatric cardiologists. Infants with struc-
tural heart disease other than a patent ductus arteriosus
(PDA) or patent foramen ovale and those with multiple
congenital anomalies were excluded.
Data collection
Data were collected from the infants’ medical records. Data
extracted included baseline demographic information,
respiratory support at 36 weeks postmenstrual age, diagno-
sis and severity of BPD, other co-morbidities of prematurity
including PDA, severe intraventricular hemorrhage, proven
necrotizing enterocolitis, medications used for treatment of
PH, and serum BNP levels. Peak BNP level was defined as
the highest BNP concentration measured during the course
of the hospitalization. The primary study outcome was all
cause mortality.
BNP for screening and follow-up of PH
The use of BNP as an adjunct to echocardiography for
screening and follow-up of BPD-associated PH has been
adopted by our group since August 2010. ELBW infants
who remained on oxygen and/or respiratory support at
28 days of age were evaluated with echocardiography and
serum BNP measurement shortly thereafter (before 6 weeks
of age) to screen for PH. Infants diagnosed with PH based
on echocardiographic findings were then evaluated with
monthly echocardiography and BNP testing for follow-up
of severity of PH. Infants who did not show signs of PH on
initial screening may be subsequently re-evaluated by echo-
cardiography and BNP measurement based on clinical sus-
picion of PH. BNP levels were measured in pg/mL using
the ADVIA Centaur® BNP Assay (Siemens USA).Our general management strategy for PH in BPD infants
utilizes a stepwise approach. Initial treatment included opti-
mizing respiratory support to provide adequate oxygenation
and prevent periods of hypoxemia. If oxygenation remains
labile, pulmonary vasodilator therapy is added sequentially
starting with inhaled nitric oxide, then sildenafil, and, for
severe cases of PH, bosentan is sometimes considered.
Statistical analyses
Values are presented as counts and percentages,
mean ± standard deviation, or median and interquartile
range (IQR, 25th and 75th percentile). Skewed data
(BNP levels) were transformed logarithmically to produce
a normal distribution for appropriate parametric testing.
Comparison of baseline subject characteristics in survivors
vs. non-survivors was performed with independent samples
t-test, Mann–Whitney U, or Fisher’s exact test, as ap-
propriate. Possible correlations between demographic
and clinical variables and outcome were investigated using
uni-and multivariate Cox proportional hazard analysis and
hazard ratios with two-sided 95% confidence interval (CI)
are provided. Before performing survival analysis, a receiver
operating characteristic curve was created to determine
the peak BNP level that provided the best combination
of sensitivity and specificity for predicting the composite
endpoint. Survival analysis was performed with Kaplan-
Meier and Cox proportional hazards modeling. The log-
rank test was used to determine statistical significance
between Kaplan-Meier survival curves. BNP level, age, sex,
and BPD severity were all included in the hazard model.




During the study period, 36 preterm infants with BPD-
associated PH had BNP values available. The mean gesta-
tional age was 26.0 ± 1.9 weeks and the mean birth weight
was 740 ± 290 grams. The differences in characteristics be-
tween survivors and non-survivors are shown in Table 1.
No differences were seen between survivors and non-
survivors in terms of gestational age, birth weight, sex, or
race. There were also no differences in terms of being small
for gestational age (SGA), respiratory support at 36 weeks
postmenstrual age and severity of BPD, severe intraventric-
ular hemorrhage, or proven necrotizing enterocolitis. Of
note, 6 of the 17 survivors (35%) were noted to have a PDA
at the time of echocardiographic diagnosis of PH compared
to none of the non-survivors (P = 0.006).
Relation of peak BNP and mortality from all causes
The median peak BNP level was significantly lower
among infants who survived than among those who died
(128 pg/ml, [IQR 23 to 463] vs. 997 pg/ml, [IQR 278 to
Table 1 Baseline and clinical characteristics for all patients, survivors and non-survivors
All patients Survivors Non-survivors P value
n = 36 n = 17 n = 19
Demographics
Birth weight, grams 740 ± 290 745 ± 293 736 ± 295 0.92
Gender, Male 19 (53) 9 (53) 10 (53) 1.0
Race 0.86
Caucasian 15 (42) 7 (41) 8 (42)
African American 20 (55) 9 (53) 11 (58)
Hispanic 1 (3) 1 (6) 0 (0)
Gestational age, weeks 26.0 ± 1.9 26.2 ± 2.4 25.8 ± 1.4 0.59
Small for gestational age 13 (36) 6 (35) 7 (37) 1.0
Respiratory support at 36 weeks postmenstrual age 0.62
Mechanical ventilation 15 (42) 8 (47) 7 (37)
CPAP 5 (14) 1 (6) 4 (21)
O2 supplementation 13 (36) 7 (41) 6 (32)
Room air 3 (8) 1 (6) 2 (10)
Morbidity
BPD 0.61
Mild 3 (8) 1 (6) 2 (10.5)
Moderate 2 (6) 0 (0) 2 (10.5)
Severe 31 (86) 16 (94) 15 (79)
Patent ductus arteriosus 6 (16) 6 (35) 0 (0) 0.006
Severe intraventricular hemorrhage (grade 3 or 4) 9 (25) 6 (35) 3 (8) 0.26
Proven necrotizing enterocolitis (stage 2 or 3) 5 (14) 4 (24) 1 (5) 0.17
Peak BNP, pg/mL 351 (82,1461) 128 (23,463) 997 (278,1770) 0.004
Medications
Inhaled nitric oxide 32 (89) 13 (76) 19 (100) 0.04
Sildenafil 31 (86) 12 (71) 19 (100) 0.02
Bosentan 18 (50) 7 (41) 11 (58) 0.51
Data shown as n (%), mean ± standard deviation, or median (interquartile range). P values refer to independent samples t-test, Mann–Whitney U, or Fisher’s
exact test.
BNP B-type natriuretic peptide, BPD bronchopulmonary dysplasia, CPAP continuous positive airway pressure, O2 oxygen.
Cuna et al. BMC Pediatrics 2014, 14:68 Page 3 of 6
http://www.biomedcentral.com/1471-2431/14/681770], P < 0.004) (Figure 1). Analysis using a receiver
operating characteristic curve shown in Figure 2 iden-
tified a peak BNP cutoff value of 220 pg/ml to have the
best combination of sensitivity (90%) and specificity
(65%) for predicting mortality from all causes.
Comparison of baseline characteristics between subjects
with peak BNP < 220 pg/ml and those with ≥ 220 pg/ml
showed no significant differences. Kaplan-Meier sur-
vival analysis shown in Figure 3 demonstrated signifi-
cantly lower survival for subjects with peak BNP level
of ≥ 220 pg/ml After controlling for age, sex, and BPD
severity, multivariate Cox proportional hazards modeling
showed that a BNP level of ≥ 220 pg/ml independently
increased the likelihood of death (hazard ratio 5.1, 95% CI
1.1 to 22.4, P = 0.03).Discussion
Our study demonstrates that peak BNP level obtained
during the course of hospitalization in a cohort of preterm
infants with BPD-associated PH provides prognostic infor-
mation on all-cause mortality. This is consistent with previ-
ous studies suggesting that elevated BNP is associated with
increased mortality in adult patients with various forms of
PH [12,14,16]. Our group has also previously demonstrated
that BNP levels may be useful in screening for PH in pre-
term infants with BPD [18]. The findings of this current
study extend the clinical usefulness of BNP as a prognostic
biomarker in preterm infants with BPD-associated PH.
Preterm infants with BPD-associated PH are difficult to
manage. Availability of a non-invasive and readily available

















Figure 1 Box plots showing median levels of peak BNP of
survivors versus non-survivors in a cohort of preterm infants
with BPD-associated PH.
Figure 3 Kaplan-Meier cumulative survival curves showing
cumulative rates of survival for 36 preterm infants with
BPD-associated PH stratified by the identified BNP cut-off value.
Infants with BNP≥ 220 pg/ml differed significantly from infants
with BNP < 220 pg/ml.
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fants are at increased risk and which are at low risk for ad-
verse outcomes allows appropriate allocation of resources
to infants who would benefit the most from specific
treatment strategies, as well as prevent overtreatment of
infants at low risk. Currently, echocardiography is used toFigure 2 Receiver operating characteristic curve demonstrating
that a BNP level of 220 pg/ml results in a sensitivity of 90%
and a specificity of 65% for predicting mortality in preterm
infants with BPD-associated PH.determine severity of PH and assess risk for adverse out-
comes. Though noninvasive and available in most centers,
echocardiography is resource intensive and has limited
sensitivity in determining severity of PH [20].
Our study suggests that elevated BNP levels may be
useful for risk stratification in this vulnerable patient
population. Our analysis was limited due to the small
sample size and the fact that BNP measurements were
not obtained at similar time points. Nevertheless, we
did observe trends showing that BNP levels decreasing
over time were seen among infants that survived; and
that BNP levels increasing or remaining elevated over time
were seen among infants who died. This observation
needs further validation in a larger prospective study
with well-defined BNP estimation time points, but it
does suggest that serial BNP measurement may be helpful
in identifying infants at high and low risk for mortality;
and that treatment, including the intensity of surveillance
and the use of aggressive pharmacologic and interventional
therapy, may be adjusted accordingly.
More than one-third of infants with BPD-associated
PH in our study were SGA. This is consistent with previous
studies which reported that SGA infants are at an increased
risk for developing PH [5,21]. It is interesting to note
however that no difference in SGA status between sur-
vivors and non-survivors was seen in our study. This
may indicate that despite the higher risk for developing
PH, SGA infants are not necessarily at any greater risk
for mortality compared to appropriate for gestational
age infants with PH. Larger prospective studies will
need to be carried out to validate this hypothesis.
It is also interesting to note that the presence of a
PDA at the time of initial echocardiographic diagnosis
of PH was noted in 6 of the 17 survivors versus none in
those who died. We postulate that the presence of a PDA
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elevated pulmonary pressures [22,23]. Another difference is
that more non-survivors were noted to be on inhaled nitric
oxide or sildenafil than survivors. This most likely repre-
sents more severe disease among non-survivors requiring
more intensive treatment for PH rather than any perceived
harm from inhaled nitric oxide or sildenafil.
Four infants with peak BNP levels below the identified
threshold of 220 pg/ml had late mortality, as reflected by
a drop in their Kaplan-Meier survival curve at around
400 days of life. (Figure 3) Review of medical records
indicate that the cause of death in 2 of these infants
were due to disease processes not directly related to PH
(sepsis, withdrawal of support for severe encephalopathy),
which may explain why BNP levels remained below the
threshold in these non-survivors. The remaining 2 infants
however were identified to have died because of severe
BPD and PH. This finding suggests that in a small subset
of preterm infants, BNP levels may not rise as expected
despite the presence of severe PH. Further studies are
needed to validate this observation as well as identify
characteristics that may determine which infants with
PH fail to exhibit a rise in serum BNP.
The strengths of our study include its well defined cohort
of preterm infants with BPD-associated PH and highly
relevant primary outcome of mortality versus survival.
Our study is limited by its small sample population, its
retrospective nature, and the possibility that infants in-
cluded are biased towards those with more severe disease.
An important limitation is the lack of follow-up data on
survivors, including rehospitalization and post-discharge
mortality. Another limitation is our lack of data on renal
function, as renal dysfunction is known to contribute to
higher BNP levels [24,25]. A prospective study involving a
larger sample size is needed to validate the usefulness of
BNP as a prognostic marker in this population. Further
studies are also needed to show whether treatment strat-
egies guided by BNP levels will lead to decreased morbid-
ity and mortality.
Conclusion
Our findings suggest that elevated BNP levels in hospi-
talized preterm infants with BPD-associated PH may be
used to identify infants at risk for death. BNP levels may
be included in the risk stratification of preterm infants
with PH, and higher BNP levels may warrant increased
surveillance and management.
Abbreviations
BNP: B-type natriuretic peptide; BPD: Bronchopulmonary dysplasia;
CI: Confidence interval; ELBW: Extremely low birth weight; IQR: Interquartile
range; PH: Pulmonary hypertension; PDA: Patent ductus arteriosus;
SGA: Small for gestational age.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
AC contributed to the design of the study, was responsible for the
management and retrieval of data from the neonatal database, contributed
to initial data analysis and interpretation, drafted the initial manuscript, and
approved the final manuscript as submitted. JK was responsible for the
management and retrieval of data from the neonatal database, contributed
to initial data analysis and interpretation, and approved the final manuscript
as submitted. BS conceptualized and designed the study, supervised all
aspects of the study, critically reviewed and revised the manuscript, and
approved the final manuscript as submitted. All authors read and approved
the final manuscript.Acknowledgements
The authors would like to acknowledge the Division of Neonatology at
University of Alabama at Birmingham for their support and guidance in the
performance of this study. No external funding was secured for this study, and
the authors have no financial relationships relevant to this article to disclose.
Received: 10 December 2013 Accepted: 4 March 2014
Published: 11 March 2014References
1. Hislop AA, Haworth SG: Pulmonary vascular damage and the
development of cor pulmonale following hyaline membrane disease.
Pediatr Pulmonol 1990, 9(3):152–161.
2. Goodman G, Perkin RM, Anas NG, Sperling DR, Hicks DA, Rowen M:
Pulmonary hypertension in infants with bronchopulmonary dysplasia.
J Pediatr 1988, 112(1):67–72.
3. An HS, Bae EJ, Kim GB, Kwon BS, Beak JS, Kim EK, Kim HS, Choi JH, Noh CI,
Yun YS: Pulmonary hypertension in preterm infants with
bronchopulmonary dysplasia. Korean Circ J 2010, 40(3):131–136.
4. Slaughter JL, Pakrashi T, Jones DE, South AP, Shah TA: Echocardiographic
detection of pulmonary hypertension in extremely low birth weight
infants with bronchopulmonary dysplasia requiring prolonged positive
pressure ventilation. J Perinatol 2011, 31(10):635–640.
5. Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N: Prospective analysis
of pulmonary hypertension in extremely low birth weight infants.
Pediatrics 2012, 129(3):e682–e689.
6. Kumar VH, Hutchison AA, Lakshminrusimha S, Morin FC, Wynn RJ, Ryan RM:
Characteristics of pulmonary hypertension in preterm neonates.
J Perinatol 2007, 27(4):214–219.
7. Kim GB: Pulmonary hypertension in infants with bronchopulmonary
dysplasia. Korean J Pediatr 2010, 53(6):688–693.
8. Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC,
Mullen MP: Pulmonary artery hypertension in formerly premature infants
with bronchopulmonary dysplasia: clinical features and outcomes in the
surfactant era. Pediatrics 2007, 120(6):1260–1269.
9. Collaro JM, Romer LH, Stuart BD, Coulson JD, Everett AD, Lawson EE,
Brenner JI, Brown AT, Nies MK, Sekar P, Nogee LM, McGrath-Morrow SA:
Frontiers in pulmonary hypertension in infants and children with
bronchopulmonary dysplasia. Pediatr Pulmonol 2012, 47(11):1042–1053.
10. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998,
339(5):321–328.
11. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in
cardiovascular disease. Lancet 2003, 362(9380):316–322.
12. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T:
N-terminal pro-B-type natriuretic peptide as an indicator of disease
severity in a heterogeneous group of patients with chronic precapillary
pulmonary hypertension. Am J Cardiol 2006, 98(4):525–529.
13. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi
S, Hamada S, Kakishita M, Nakanishi N, Takamiya M, Kunieda T, Matsuo H,
Kangawa K: Plasma brain natriuretic peptide levels increase in proportion
to the extent of right ventricular dysfunction in pulmonary
hypertension. J Am Coll Cardiol 1998, 31(1):202–208.
14. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita
M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K: Plasma
brain natriuretic peptide as a prognostic indicator in patients with
primary pulmonary hypertension. Circulation 2000, 102(8):865–870.
15. Goto K, Arai M, Watanabe A, Hasegawa A, Nakano A, Kurabayashi M: Utility
of echocardiography versus BNP level for the prediction of pulmonary
Cuna et al. BMC Pediatrics 2014, 14:68 Page 6 of 6
http://www.biomedcentral.com/1471-2431/14/68arterial pressure in patients with pulmonary arterial hypertension.
Int Heart J 2010, 51(5):343–347.
16. Mauritz GJ, Rizopoulos D, Groepenhoff H, Tiede H, Felix J, Eilers P, Bosboom J,
Postmus PE, Westerhof N, Vonk-Noordegraaf A: Usefulness of serial N-terminal
pro-B-type natriuretic peptide measurements for determining prognosis
in patients with pulmonary arterial hypertension. Am J Cardiol 2011,
108(11):1645–1650.
17. Jobe AH, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care
Med 2001, 163(7):1723–1729.
18. Cuna A, Kandasamy J, Fineberg N, Sims B: B-type natriuretic peptide is a
biomarker for pulmonary hypertension in preterm infants with
bronchopulmonary dysplasia. Res Rep Neonatology 2013, 2013(3):33–36.
19. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R: N-terminal
pro-B-type natriuretic peptide and long-term mortality in stable coronary
heart disease. N Engl J Med 2005, 352(7):666–675.
20. Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH: Clinical utility of
echocardiography for the diagnosis and management of pulmonary
vascular disease in young children with chronic lung disease.
Pediatrics 2008, 121(2):317–325.
21. Check J, Gotteiner N, Liu X, Su E, Porta N, Steinhorn R, Mestan KK: Fetal
growth restriction and pulmonary hypertension in premature infants
with bronchopulmonary dysplasia. J Perinatol 2013, 33(7):553–557.
22. Hines MH: Invited commentary. Ann Thorac Surg 2006, 81(1):234–235.
23. Rosenzweig EB, Feinstein JA, Humpl T, Ivy DD: Pulmonary arterial
hypertension in children: diagnostic work-up and challenges. Prog Pediatr
Cardiol 2009, 27(1):4–11.
24. DeFilippi CR, Seliger SL, Maynard S, Christenson RH: Impact of renal disease
on natriuretic peptide testing for diagnosing decompensated heart
failure and predicting mortality. Clin Chem 2007, 53(8):1511–1519.
25. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE,
Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham
WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R,
Maisel AS, Breathing Not Properly Multinational Study Investigators: B-type
natriuretic peptide and renal function in the diagnosis of heart failure:
an analysis from the breathing Not properly multinational study.
Am J Kidney Dis 2003, 41(3):571–579.
doi:10.1186/1471-2431-14-68
Cite this article as: Cuna et al.: B-type natriuretic peptide and mortality
in extremely low birth weight infants with pulmonary hypertension: a
retrospective cohort analysis. BMC Pediatrics 2014 14:68.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
